Get the latest news, insights, and market updates on VKTX (Viking Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735
Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its Phase 3 VANQUISH-1 clinical trial of subcutaneous VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations fo Nov 19, 2025 - $VKTX
Viking Therapeutics (VKTX): Assessing Valuation Following Recent 16.6% Share Price Rebound
Viking Therapeutics (VKTX) shares have seen some interesting moves over the past month, climbing more than 16%. Investors are watching closely, with a particular focus on how the biotech’s pipeline could be a factor in driving future growth. See our latest analysis for Viking Therapeutics. Viking Therapeutics’ recent rally comes after a volatile stretch, with a notable 16.6% 30-day share price return helping offset some challenging months for long-term holders. Even with the recent gains and... Nov 17, 2025 - $VKTX
ObesityWeek 2025: Breakthrough Results Reshaping the Obesity Market Landscape | DelveInsight
The annual conference presented over 100 scientific sessions featuring innovations from leading pharmaceutical companies, including Novo Nordisk, Eli Lilly and Company, Viking Therapeutics, Ascletis Pharma, Skye Bioscience, Palatin Technologies, Inc., Neurogastrx, Inc., OrsoBio, Metsera, and others, revealing not only significant advances in drug efficacy but also reshaping the multibillion-dollar obesity therapeutics market. These presentations collectively demonstrate that obesity management h Nov 13, 2025 - $VKTX
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
According to the average brokerage recommendation (ABR), one should invest in Viking Therapeutics (VKTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock? Nov 12, 2025 - $VKTX
William Blair Reiterates “Buy” Rating on Viking Therapeutics (VKTX) Following New VK2735 Data
With significant upside potential and hedge fund interest, Viking Therapeutics, Inc. (NASDAQ:VKTX) secured a spot on our list of the 15 stocks set to explode in 2026. On November 6, 2025, Viking Therapeutics Inc. (NASDAQ:VKTX) discussed new VK2735 data at ObesityWeek 2025, highlighting that results from its Phase 2 VENTURE trial showed 78% of treated […] Nov 11, 2025 - $VKTX
Will New Cardiometabolic Data on VK2735 Shift Viking Therapeutics' (VKTX) Obesity Treatment Narrative?
Viking Therapeutics recently presented new clinical data at ObesityWeek 2025, highlighting significant improvements in weight loss, prediabetes, and metabolic syndrome for patients treated with its dual GLP-1/GIP agonist VK2735 compared to placebo after 13 weeks. Importantly, the analysis showed that VK2735’s effects on cardiometabolic health extended beyond weight reduction, with a substantial proportion of patients achieving normal glycemic status and improved metabolic profiles. We'll... Nov 7, 2025 - $VKTX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple